Damon Runyon Researchers

Meet Our Scientists
Ali Lashkaripour, PhD

The astonishing diversity of T cells makes finding ones that specifically target tumor cells but not host cells a major challenge in developing T cell immunotherapies. For this reason, the adoption of T cell immunotherapies in clinical settings has been slow despite their remarkable potential. Dr. Lashkaripour is developing a microfluidic platform capable of screening millions of T cells against millions of tumor antigens per day to identify the stimulatory pairs that drive an efficient immune response. With this research, he hopes to establish the groundwork for deciphering the rules of sequence-dependent T cell recognition of antigens. This research may guide the development of more effective and safer cancer immunotherapies. Dr. Lashkaripour received his PhD from Boston University, his MSc from the University of Tehran, and his BSc from Ferdowsi University of Mashhad.

Project title: "High-throughput biomimetic screening of T cell activation in large sequence landscapes"
Institution: Stanford University School of Medicine
Award Program: Fellow
Sponsor(s) / Mentor(s): Polly M. Fordyce, PhD
Cancer Type: All Cancers
Research Area: Basic Immunology